Search Results

Explore Martin Marro’s impact on GPCR drug discovery, assay innovation, and translational pharmacology bridging academia, pharma, and biotech. << Back to podcast list Strategic Partner(s) GPCR Assay Strategy Marro’s career spans big pharma and biotech, encompassing functional assay development, GPCR internalization How advanced assay design is essential for translating cell-based GPCR signals to therapeutic outcomes development, small molecule and biologics research, and team leadership through high-profile programs

Michelle Halls reveals how organized GPCR signaling drives assay innovation and new therapeutic insights This conversation is especially valuable for scientists developing functional assays, fluorescence-based development and GPCR research. Why It Might Hit Home If you’ve ever: Faced unexpected assay behavior at ultra-low ligand concentrations Get behind-the-scenes conversations, advanced assay development strategies, and practical GPCR tools

taste receptors in cancer and metabolic diseases, and emerging high-throughput methods for functional assay development. generation How computational approaches and wet-lab validation complement each other in functional assay development Who Should Listen If you face complex GPCR questions at the bench or in translational research His current efforts bridge teaching in Toronto and ongoing research, including the development of an

Discover how Celtarys Research is transforming GPCR assay development with fluorescent ligands in this probes for GPCR assays. GPCR, Celtarys will bring those lessons to the broader community, providing insight into assay development Their approach is highly consultative—they don’t just sell ligands, they co-develop solutions. Whether you're designing assays, developing probes, or seeking better tools for GPCR drug discovery,

David has over 20+ years of experience working in a drug discovery environment mainly in a specialist assay development role and most recently with Novartis. His current interests include the development of HTS fluorescence-based kinetic binding assays specifically

Eric Trinquet shares the inside story behind the development of pH Sense, Revvity’s latest innovation and product development, Eric takes us through the highs, failures, and scientific “aha” moments that Inside This Episode How Eric and his team reimagined rare earth complexes to develop pH-sensitive probes and hit the “overexpression ceiling,” Balanced scientific rigor with the unpredictability of product development development.

His current work is mainly focused on screening and assay development to bridge the gap between in vitro

His team develops fluorescence-based and chemically engineered tools to study gpcr internalization and engagement in intact islets and neuronal circuits — insights that inform next-generation functional assay development and translational therapeutic design. on biological context Balanced innovation with the need for reproducible, well-controlled functional assays His group develops imaging and chemical biology tools to reveal how GLP-1 and GIP receptors operate within

Insights for GPCR researchers and functional assay innovators. << Back to podcast list Strategic Partner She shares approaches that combine genetic manipulation (CRISPR-Cas9) and functional behavioral assays Listeners interested in GPCR drug discovery, functional assay development, or fluorescence-based assays Why the study of conserved receptor pathways enables the development of broadly effective, species-independent If you want to expand high-throughput or fluorescence-based assay strategies to non-traditional models

Johannes Broichhagen reveals how fluorescent probes transform GPCR imaging, internalization studies, and assay development in live cells and tissues. << Back to podcast list Strategic Partner(s) Chemical Probes Balanced creativity in tool development with the pressure for reproducible, publication-grade data. Tried to build assays that behave in living cells—not just on paper. research group at the Leibniz Research Institute for Molecular Pharmacology (FMP) in Berlin, focusing on developing

His research spans BRET-based assay platforms for characterizing signaling downstream of specific GPCRs His work is grounded in careful assay development and a conviction that the signaling space around a BRET platforms for GPCR signaling — The role of resonance-energy-transfer-based assays in capturing signaling Vaccine development at scale — How to read a landscape of 90+ parallel vaccine candidates without confusing BRET-based platform for capturing downstream signaling, built with the Bouvier lab — illustrates how assay-development

Podcast , leaders from academia and biotech unpack what effective collaboration really looks like when developing development benefits from scalable distribution rather than ad-hoc sharing. Listen This episode is for scientists and leaders who are: Navigating the transition from academic tool development co-founding the company in 2021, she has led all scientific activities, from proprietary technology development His research focuses on bottom-up chemical tool development for imaging and interrogating GPCRs and other

Accelerated Program Progression: Design robust assay cascades and establish key go/no-go points to speed development to CRO selection or portfolio strategy, ensuring a tailored approach. 3 Collaborative Execution Accelerated Preclinical Progression I streamline critical operational processes, from advanced assay Small missteps can derail entire programs: underperforming assays, off-track CROs, and data that fails Before working with Yamina, we had solid internal momentum but needed to better align our biology, assay

For Gloriam, this work began with a grandmother's cancer diagnosis and an early determination to develop sequence-based phylogeny, database mining for tissue expression, virtual screening, pharmacological assay development, machine learning-guided ligand identification, and finally structural collaboration with For me, the actual development - that's the thing. And that's the fun part." His group recently developed an online resource of biased ligands and pathway effects to advance the

She trained in high-throughput drug discovery at Vanderbilt - contributing to early functional assay development for metabotropic glutamate and muscarinic receptors - before completing postdoctoral training

Using radioligand binding assays developed for the beta-adrenergic receptor system, his lab purified, His lab developed the GRK (G protein-coupled receptor kinase) family and discovered the beta-arrestins demonstration of GPCR structure — The methodological progression from iodinated hormone binding to radioligand development

Your One-Stop-Shop for GPCR Drug Discovery and Development Researchers developing GPCR-targeted therapeutics for basic research through therapeutic discovery and development. Assay Principle of Eurofins DiscoverX Cell-based Assays Whether you are developing small-molecule or biologic therapeutic drugs, Eurofins DiscoverX provides you with a variety of drug discovery and development Product Solutions to Support Obesity/Diabetes See GLP-1 Solutions Accelerating Obesity Therapeutics Development

Pfleger on NanoBRET live-cell assays, receptor complex pharmacology, and what it took to move GPCR biology His group developed BRET and NanoBRET-based live-cell platforms that capture protein-protein interactions He developed BRET and NanoBRET-based live-cell assay platforms now widely adopted across the GPCR field The development of NanoBRET - including live-cell ligand binding assays built on CRISPR-expressed receptors Professor Pfleger has developed extensive expertise in profiling receptor binding and function at the

the biological basis of signaling bias, shows how to detect and quantify it using reliable functional assays Organizers Eurofins DiscoverX Eurofins DiscoverX is a one-stop-shop for GPCR drug discovery and development Their assays are industry-standard, accepted for regulatory potency testing, and backed by thousands scientists and biotech leaders working across pharmacology, translational research, and therapeutic development Curated intelligence on GPCR drug discovery trends and developments Expert-led webinars and masterclasses

He currently leads Revvity's Research and Development activities, focusing on biochemical and cellular Before joining Revvity, Eric worked for Cisbio Bioassays first as Director of Technological Development department, leading her team on the development of innovative HTRF™ and AlphaLISA™ kits for pharma, Eric Trinquet, Director of Research and Development at Revvity. ™ was developed to overcome three persistent barriers in internalization studies: Complexity of imaging-based

Visit Website About Celtarys Research Celtarys Research develops and commercializes new chemical tools Her work focuses on organic synthesis, medicinal chemistry, and the development of GPCR-targeted tools Celtarys Research develops high-quality, fluorescently labeled ligands and innovative chemical biology Custom Development Customized fluorescent ligands developed in less than 3 months with optimal properties Custom Development Tailored fluorescent probes designed for unique research requirements.

behind each transition: from chemistry to pharmacology, from membrane to endosome, from bench to product development "You have to know what your assay is actually measuring. John Traynor , Kathryn worked to develop and understand first-in-class allosteric modulators of opioid There she researched the beta-2 adrenergic receptor and developed assays to investigate real-time activity Kathryn’s passion is developing solutions to problems in whatever form is most efficient: novel instrumentation

During my PhD, I learnt radioligand binding assays, behavioral assays, autoradiography, stereotaxic surgeries nervous system disorders realm to understand the neurobiology of neuropsychiatric disorders and to develop

in collaboration with: Celtarys Research Fluorescent Probes for GLP-1R and GIPR Imaging: From Cell Assays This webinar introduces two families of advanced fluorescent probes developed specifically for working His research group develops and applies novel technologies to investigate GLP-1 and GIP receptors — two Organizers Celtarys Research Celtarys develops and commercializes fluorescent chemical tools and related Curated intelligence on GPCR drug discovery trends and developments Expert-led webinars and masterclasses

Khorana’s lab made early key contributions and developed strategies to express, reconstitute and assay He also went on to discover a “counterion switch” in visual pigments and to develop strategies to assay Howard Hughes Medical Institute appointment, Tom advanced a series of novel biochemical and biophysical assay Tom’s lab also developed an amber codon suppression method to genetically encode unnatural amino acids Early applications included “targeted photo-crosslinking,” and more recently, the parallel development

Maria Waldhoer on why endpoint GPCR assays miss most of what ligands do — and what kinetic pharmacological Maria Waldhoer, CSO of InterAx Biotech AG, argues that endpoint assays — the field's default way of characterizing InterAx models receptor signaling pathways as systems of time-dependent equations, then runs kinetic assays She has been at InterAx since 2017, where she leads the development of a computational systems biology , data The academic-to-Big-Pharma-to-biotech trajectory Key Insights from the Conversation Endpoint assays

The conversation ended with Arthur's ongoing research and his development of a new operational model. Allosteric Modulation and Hybrid Molecules Arthur and Yamina discussed the development of an operational Arthur recounted a 2004 visit to a pharma company using replicates in assays. also discussed the potential of certain drugs, like flumazenil, as 'nails' or compounds that could be developed and Reproducibility Yamina and Arthur discussed the concept of a target product profile (TPP) in drug development

It is also a matter of G protein coupling, tissue context, and the signaling assay used to measure affinity PhD candidate at the University of Nottingham and the Monash Institute of Pharmaceutical Sciences, is developing the design and synthesis of fluorescent ligands for adenosine A1 and A2A receptors, with the goal of developing Affinity is not a fixed property - it is assay-dependent The apparent affinity of adenosine for its own A cAMP assay and a binding assay using the same receptor and the same ligand can return different affinity

Karine Pichavant , I contributed to the development of a drug to treat hypovolemic shock after severe MRAP2 regulates GHSR1a signaling; this project brought forth our NanoBiT-based arrestin recruitment assay This powerful tool allowed us to create an assay that kinetically measured the arrestin recruitment to Chemistry which described the molecular mechanisms of MRAP2 regulation of the GHSR1a, and where I notably developed I also invested a tremendous amount of time in developing my leadership skills.

His independent research focuses on developing accessible mathematical tools for kinetic analysis of The Off-Rate That Saved a Program Standard binding assays showed identical affinity. The Neurocrin team had to confront an explanation no assay had been designed to find — and then built consultancy and data analysis company supporting pharmaceutical, life science, and academic scientists in the development He specializes in kinetic analysis of drug action and is known for applying binding kinetics to the development